Published in final edited form as:

J Stroke Cerebrovasc Dis. 2019 February ; 28(2): 360–368. doi:10.1016/j.jstrokecerebrovasdis.2018.10.004.

Differential expression of vascular endothelial growth factor-A₁₆₅ isoforms between intracranial atherosclerosis and moyamoya disease

Hao Jiang, MD^{1,2}, Juan F. Toscano, BS¹, Michael Schiraldi, MD, PhD¹, Shlee S. Song, MD⁴, Konrad H. Schlick, MD⁴, Oana M. Dumitrascu, MD⁴, Raymond Liou, BS³, Patrick D. Lyden, MD⁴, Jianwei Pan, MD, PhD², Renya Zhan, MD, PhD², Jeffrey L. Saver, MD⁵, Nestor R. Gonzalez, MD.^{1,†}

¹Department of Neurosurgery – Gonzalez Neurovascular Laboratory. Cedars-Sinai Medical Center. Los Angeles, California, U.S.A.

²Department of Neurosurgery – The First Affiliated Hospital of Zhejiang University – School of Medicine. Hangzhou, China.

³Stanford University – School of Medicine. Palo Alto, California, U.S.A.

⁴Department of Neurology. Cedars-Sinai Medical Center. Los Angeles, California, U.S.A.

⁵Department of Neurology. University of California Los Angeles. Los Angeles, California, U.S.A.

Abstract

Background—Vascular endothelial growth factor-A₁₆₅ (VEGF-A₁₆₅) has been identified as a combination of two alternative splice variants: proangiogenic VEGF-A_{165a} and antiangiogenic VEGF-A_{165b}. Intracranial atherosclerotic disease (ICAD) and moyamoya disease (MMD) are two main types of intracranial arterial steno-occlusive disorders (ICASD) with distinct capacities for collateral formation. Recent studies indicate that VEGF-A₁₆₅ regulates collateral growth in ischemia. Therefore, we investigated if there is a distinctive composition of VEGF-A₁₆₅ isoforms in ICAD and MMD.

Methods—Sixty-six ICAD patients, six MMD patients, and five controls were enrolled in this prospective study. ICAD and MMD patients received intensive medical management upon enrollment. Surgery was offered to 9 ICAD patients who had recurrent ischemic events, 6 MMD patients, and 5 surgical controls without ICAD. VEGF-A_{165a} and VEGF-A_{165b} plasma levels

[†]*Corresponding Author: Nestor R. Gonzalez, MD*, Professor of Neurosurgery, Vascular and Endovascular Neurosurgery, Director of Neurovascular Laboratory, Cedars-Sinai Medical Center, Advanced Health Sciences Pavilion (AHSP), Address: 127 So. San Vicente Blvd, 6th. floor, Suite A6600, Los Angeles, CA 90048, Phone: (310) 423-0783 or (310) 423-7900, Fax: (424)-315-2222, nestor.gonzalez@cshs.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

DISCLOSURES

None

were measured at baseline, within one week after patients having surgery, and at one, three, and six months after treatment.

Results—A significantly higher baseline VEGF-A_{165a/b} ratio was observed in MMD compared to ICAD ($p=0.016$). The VEGF-A_{165a/b} ratio increased significantly and rapidly after surgical treatment in ICAD ($p=0.026$) more so than in MMD and surgical controls. In patients with ICAD receiving intensive medical management, there was also an elevation of the VEGF-A_{165a/b} ratio, but at a slower rate, reaching the peak at three months after initiation of treatment (baseline vs. three months VEGF-A_{165a/b} ratio, $p=0.028$).

Conclusions—Our study shows an increased VEGF-A_{165a/b} ratio in MMD compared to ICAD, and suggests that both intensive medical management and surgical revascularization elevate the VEGF-A_{165a/b} ratio in ICAD patients.

Keywords

VEGF-A₁₆₅; Isoforms; Intracranial atherosclerosis; Moyamoya disease

INTRODUCTION

The vascular endothelial growth factor (VEGF) family of proteins are key angiogenic regulators in both physiological and pathological conditions. Among all the members of this family, VEGF-A is the best known and most potent angiogenic protein¹. VEGF-A has different variants, among which VEGF-A₁₆₅ is believed to be the dominant form binding to all receptors.² Previously, all VEGF-A isoforms were thought to be proangiogenic. Recently, VEGF-A₁₆₅ has been identified as a combination of two alternative splice variants (isoforms _{165a} and _{165b})³ VEGF-A_{165b} is a powerful competitive innate inhibitor of the angiogenic effect of VEGF-A_{165a}.⁴ To the best of our knowledge, no investigations of the role of these isoforms have been conducted in cerebrovascular diseases.

Intracranial arterial steno-occlusive disorders (ICASD) are some of the most common causes of stroke worldwide.^{5, 6} Chronic progression of arterial stenosis may allow collaterals to develop over time, which could potentially offset the hemodynamic impairment induced by stenosis. Several recent studies show that collaterals dramatically alter stroke risk and functional outcome in ICASD.^{7–9} Intracranial atherosclerotic disease (ICAD) is the most common subtype of ICASD. Unfortunately, the extent of collaterals in ICAD is limited. Only 20% of patients with ICAD stenosis of more than 50% have good collaterals.¹⁰ This factor may be key in the worse prognosis of ICAD patients when compared to other stroke etiologies.^{11–13} Conversely, another type of ICASD, moyamoya disease (MMD), is known for its pronounced collateral formation.¹⁴

Growing evidence indicates that ischemia-induced collateral growth in different pathologies is regulated by VEGF-A.^{15, 16, 17} However, prior studies comparing plasma levels of VEGF between ICAD and MMD patients have not found differences.^{18, 19} Of note, the role of VEGF isoforms has not been evaluated.

In the present study, we hypothesized that there is a distinctive pattern of the levels of VEGF-A_{165a} and VEGF-A_{165b} in patients with ICAD and MMD. In addition, we evaluated

the regulatory effects of intensive medical management and surgical revascularization on VEGF-A₁₆₅ isoforms.

MATERIALS AND METHODS

Population and study design

Population: Patients diagnosed with ICASD in four hospitals in the Los Angeles metropolitan area between 2012 and 2014 were enrolled in this prospective cohort study. A diagnosis of severe stenosis (70%) of an intracranial large artery was confirmed by catheter, CT, or MR angiography. The eligibility of the patients was assessed according to the inclusion and exclusion criteria listed in Table 1. The diagnosis of ICAD or MMD was adjudicated based on the standardized criteria in Table 2. In order to include surgical controls without cerebrovascular disease, intracranial tumor, or infectious or inflammatory problems, a group of patients with epilepsy who would potentially undergo subdural grid or depth electrode placement were enrolled. The study was approved by the local institutional review boards, and informed consent of each participant was obtained.

Intervention: Immediately upon enrollment, all patients with ICASD received antiplatelet treatment. Patients with ICAD had a strict management of primary vascular risk factors (systolic blood pressure and low-density lipoprotein [LDL]) and secondary vascular risk factors (diabetes, non-high-density lipoprotein [non-HDL], smoking, obesity, and inadequate physical activity). If a patient with ICAD had events of stroke or transient ischemic attacks (TIA) despite intensive medical management, they were considered for surgical revascularization. All patients with MMD were offered surgical revascularization. All surgical patients were treated with encephaloduroarteriosynangiosis (EDAS) according to our formerly published protocols.^{20, 21} Intensive medical management, including the use of aspirin, was continued without interruption during the perioperative period. All the patients underwent regular follow-up visits at one, three, and six months.

VEGF-A Isoforms Level Determination

For ICAD patients, blood samples were collected at baseline and then during follow-up visits at one, three, and six months. For patients who underwent surgery, additional blood samples were collected during the postoperative period, within one week after surgery. For MMD patients and surgical controls, blood samples were only collected at baseline and within one week after surgery. The sample collection and loss at each time point in specific groups was illustrated in detail via a CONSORT flow diagram (Figure 1).

Blood was collected in EDTA tubes at each time. Plasma was immediately separated by centrifugation at 3500 rpm for 15 minutes at 4°C and stored in 2 cc cryogenic vials at -80°C. Quantitative measurement was performed using an enzyme-linked immunosorbent assay (ELISA, Ciraplex® Aushon Biosystems, MA, USA) to detect the plasma level of VEGF-A_{165a} and _{165b}. Each sample was measured twice, with the mean of the two values reported as the plasma level. The mean intra-assay coefficient of variation (CV) was established with a threshold of less than 20% CV considered valid.

Statistics

Descriptive statistics were computed to summarize demographic data, medical history, and vascular risk factors in each etiology. The comparison of baseline characteristics was made by using the student's t-test for continuous variables and Fisher's exact test for categorical variables.

The VEGF-A_{165a/b} ratio was calculated by dividing the VEGF-A_{165a} plasma level by the value of VEGF-A_{165b}. Univariate analyses were applied to evaluate the association between the baseline VEGF-A_{165a/b} ratio and etiology, together with other clinical variables including age, gender, race, vascular risk factors, and coronary artery disease. The statistical significance of the association was determined by the Wilcoxon Rank Sum test (nonparametric comparison) and Kruskal-Wallis test (multiple nonparametric comparisons) for categorical variables and linear fit for continuous variables. Clinical variables found to be potentially associated with VEGF-A_{165a/b} ratio ($p < 0.05$) in univariable analysis but unequally distributed in the different etiology groups were further analyzed within each group. If a variable remained significant, then it was considered as a confounder, and the association between etiology and VEGF-A_{165a/b} ratio was further evaluated separately within each stratum defined by the confounding variable.

The effects of the surgical intervention on the VEGF-A_{165a/b} ratio were investigated in ICAD, MMD, and controls; the values at baseline and within one week in each group were compared using the Wilcoxon Rank Sum test. The levels of VEGF-A_{165a}, VEGF-A_{165b}, and the VEGF-A_{165a/b} ratio during follow-up posttreatment were analyzed in ICAD; the values at each time point under an identical treatment were compared in pairs via the Wilcoxon Rank Sum test.

Statistical analyses were conducted using JMP statistical package, version 13.0. All the tests used were two-tailed, and $p < 0.05$ was considered significant.

RESULTS

Population characteristics

A total of 77 patients were enrolled in this study, including 66 in the ICAD group, 6 in the MMD group, and 5 in the control group. Demographic characteristics, vascular risk-factor profiles, and medical histories for each group are shown in Supplemental Table 1. The mean age of patients with MMD was 40.9 ± 11.1 years, which is significantly younger than that of patients with ICAD (61.4 ± 12.6 years, $p = 0.0013$). The majority of patients with MMD were female (5/6, 83.3%), while the proportion of female patients in ICAD and controls were 47% and 60% respectively. The most common race in ICAD and controls was White. Asians represented 66.7% of MMD patients. Hypertension was significantly more prevalent in ICAD patients ($p = 0.0003$).

Etiology and the composition of VEGF-A isoforms

A total of 188 blood samples were collected from the enrolled patients at the times described in the Methods section. For each sample, the plasma levels of VEGF-A_{165a} and VEGF-

A_{165b} were measured, and the VEGF-A_{165a/b} ratios were calculated. In the univariate analysis, a significantly higher baseline VEGF-A_{165a/b} ratio was observed in MMD compared with ICAD (0.47 ± 0.45 vs. 0.16 ± 0.15 , $p=0.016$). There was also a significantly negative association between the VEGF-A_{165a/b} ratio and age ($p=0.004$). However, age did not maintain significance in the within-group analysis, indicating that age was associated to etiology but not VEGF isoform levels. The complete results of the univariate analysis are summarized in Table 3. The total levels of VEGF-A₁₆₅ (165a plus 165b) were similar among the three groups, which were 348.3 ± 162.8 (pg/ml) in ICAD, 271.4 ± 89.3 (pg/ml) in MMD, and 327.4 ± 77.1 (pg/ml) in controls ($p=0.31$). However, VEGF-A_{165b} levels in MMD were significantly lower than in ICAD (196.9 ± 61.6 [pg/ml] vs. 308.2 ± 20.2 [pg/ml], $p=0.0006$) and controls (196.9 ± 61.6 [pg/ml] vs. 305.4 ± 84.6 [pg/ml], $p=0.007$), and VEGF-A_{165a} levels were significantly higher in MMD than in controls (74.6 ± 70.7 [pg/ml] vs. 20.6 ± 15.4 [pg/ml], $p=0.026$) but not ICAD (74.6 ± 70.7 [pg/ml] vs. 40.2 ± 33.8 [pg/ml], $p=0.092$). The highest levels of VEGF-A_{165b} were found in the ICAD group (Figure 2).

Effect of surgical intervention on the VEGF-A_{165a/b} ratio

EDAS was conducted on nine ICAD patients and six MMD patients. Five control patients received intracranial surgery, as described in the Methods section. Postoperatively, patients treated with EDAS surgery were TIA and stroke-free for the lengths of their follow-ups. The VEGF-A_{165a/b} ratio was elevated within one week after surgery in all groups. However, statistically significant elevation was observed only in ICAD patients (0.10 ± 0.06 at baseline vs. 0.27 ± 0.23 within 1 week postsurgery, $p=0.026$, Figure 3). The VEGF-A_{165a/b} ratio within one week after surgery exhibited no significant difference between MMD and ICAD (0.35 ± 0.35 in MMD vs. 0.27 ± 0.23 in ICAD, $p=0.82$).

Effect of time and type of treatment on the VEGF-A₁₆₅ isoforms in ICAD

Subgroup analyses by treatment showed distinct patterns of VEGF-A_{165a}, VEGF-A_{165b}, and the VEGF-A_{165a/b} ratio in ICAD over time (Figure 4).

For the patients with only intensive medical management, the VEGF-A_{165a/b} ratio gradually elevated until reaching its peak three months after treatment (baseline VEGF-A_{165a/b} ratio = 0.13 ± 0.12 , vs. three-month VEGF-A_{165a/b} ratio = 0.25 ± 0.23 , $p=0.028$). This is due to an increase in the VEGF-A_{165a} levels, which went from 31.36 ± 24.84 (pg/mL) at baseline to 62.73 ± 52.13 (pg/mL) at three months, $p=0.015$. The VEGF-A_{165b} levels did not change significantly over time ($p=0.38$).

For those patients who had EDAS surgery, the peak of the VEGF-A_{165a/b} ratio was achieved within one week after surgery (baseline VEGF-A_{165a/b} ratio = 0.10 ± 0.06 , vs. within-one-week VEGF-A_{165a/b} ratio = 0.27 ± 0.23 , $p=0.026$). Then, the ratio gradually declined by the six-month follow-up. In the surgical patients, the initial change in the VEGF-A_{165a/b} ratio was due to a significant decrease of VEGF-A_{165b} (baseline VEGF-A_{165b} = 401.09 ± 314.52 [pg/mL], vs. within-one-week VEGF-A_{165b} = 232.27 ± 68.54 [pg/mL], $p=0.047$).

DISCUSSION

The role of VEGF-A in vascular ischemic disease has been previously studied,^{22–24} but only a few studies have investigated the antiangiogenic action of VEGF-A_{165b} in peripheral artery disease.²⁵ To the best of our knowledge, the present study is the first investigation of the role of VEGF-A₁₆₅ isoforms in cerebrovascular diseases.

We found that VEGF-A₁₆₅ isoforms are distinct among different forms of cerebrovascular steno-occlusive disorders. Our study shows an increased VEGF-A_{165a/b} ratio in MMD compared to ICAD and controls. It also demonstrates a significant elevation of the VEGF_{165a/b} ratio within one week after surgical therapy for ICAD but not for MMD. In patients with ICAD, intensive medical management also produced an increase in the VEGF-A_{165a/b} ratio, but at a slower rate, with the ratio peaking at three months after initiation of treatment.

Previous studies have failed to detect differences in circulating VEGF between MMD and ICAD.^{18, 19} Rafat et al. found that the serum concentration of VEGF was increased in both MMD and ICAD patients compared to healthy controls but not different between the two conditions. However, circulating endothelial progenitor cells (cEPCs) were upregulated only in MMD, and the number of cEPCs was inversely correlated with the VEGF serum level.¹⁸ This seems to contradict the conventional thought that the migration, adhesion, and proliferation of cEPCs are largely dependent on VEGF.^{26, 27} In our study, the total concentration of the VEGF-A₁₆₅ isoforms was also not different between MMD and ICAD. Nevertheless, the VEGF-A_{165a/b} ratio was significantly higher in MMD. This discrepancy between VEGF levels and cEPCs upregulation found by Rafat et al. could be explained by our findings. A higher proportion of competitive inhibitor VEGF-A_{165b} neutralizes the biological effect of VEGF-A_{165a}, impairing the recruitment and activation of cEPCs in ICAD patients. On the contrary, the high ratio of VEGF-A_{165a/b} in MMD represents a positive stimulus for EPCs, which could contribute to the increased collateral formation.²⁸

The reason for the differences in the VEGF-A_{165a/b} ratio between MMD and ICAD is not clear. A possible explanation may reside in the role of insulin-like growth factor (IGF) and its ability to switch VEGF-A splicing from an antiangiogenic to a proangiogenic isoform in epithelial cell type.²⁹ Interestingly, a large number of studies have shown that lower levels of IGF-1 are associated with the presence of traditional vascular risk factors, including hypertension, hyperlipidemia, obesity, and type 2 diabetes mellitus.^{30–34} ICAD patients are prone to have these vascular risk factors, which could lead to lower levels of IGF-1. This would impede the splicing to a proangiogenic phenotype during an angiogenic response to ischemia. Such inability could contribute to a distinct capacity for ischemia-induced collateral growth between ICAD and MMD. Additionally, as we found, the antiangiogenic phenotype in ICAD patients is gradually switched by intensive medical management, which targets correction of primary and secondary vascular risk factors. The switch to a less antiangiogenic profile may improve clinical outcomes in ICAD.³⁵ We speculate that proper control of these vascular risk factors by intensive medical management benefits the increased expression of IGF-1, which favors proangiogenic splicing.

In ICAD patients, we observed a rapid increase of the VEGF-A_{165a/b} ratio within one week after EDAS surgery. The surgery itself may be regarded as an angiogenesis-inducing condition since it causes the release of various proangiogenic factors.³⁶ However, the significant elevation in ICAD and MMD patients after EDAS compared to the controls who underwent intracranial surgeries with a similar degree of tissue manipulation indicates that the baseline hypoxic status with ICAD enhances a proangiogenic response after surgery. The observation in our study that the postoperative VEGF-A_{165a/b} ratios were not different between ICAD and MMD may help to explain the results observed by Gonzalez et al., who reported angiographic neovascularization after EDAS in patients with ICAD and MMD.²¹ The postsurgical elevation of the VEGF-A_{165a/b} ratio was more prominent in ICAD. This can be explained in part by the initially higher VEGF-A_{165a/b} ratio in MMD, which may limit the proangiogenic induction in response to EDAS.

Until now, the ability of individuals to form sufficient collaterals remains a non-modifiable risk factor for stroke and only surgical techniques like indirect bypasses with EDAS surgeries provide interventions targeting the individual's ability to form collaterals. The markers we have evaluated in this study could potentially be used in the future to identify groups in whom aggressive surgical interventions could be indicated. However, the present study is an early-stage and explorative investigation of these isoforms' differential expression, and further confirmation in larger cohorts is necessary before delineating a definitive role for the VEGF-A₁₆₅ isoforms as biomarkers of ICAD.

Some limitations of our study include a relatively small sample size, particularly in the MMD and control groups. However, this reflects the more common occurrence of ICAD and the relative rareness of MMD in the United States. Some clinical covariates among the three groups cannot be exactly matched due to distinct disease features. To account for the potential confounding effects driven by these covariates, instead of using regression analysis, which is limited by the asymmetric sample size of our cohort, we conducted a within-group evaluation. The additional variables found potentially significant in the univariate analysis (age and hypertension) did not remain significant in further analysis. Second, among patients undergoing medical management there was loss of samples due to loss of follow up in 62.7%, hemolysis in 15.7% and invalid measurements in 21.6% of the 51 samples that were not collected. All patients had baseline samples and therefore the missing data would not influence the result reported on the effects of etiology on the VEGF-A₁₆₅ isoforms, which was done using exclusively the baseline data. In the same manner, the effects of surgical intervention on the groups of ICAD, MMD, and controls are not affected, as there was no sample loss at baseline and within 1 week after surgery. The expected effect of the sample loss in the patients with ICAD after 3 months postsurgery is minimal as only 2 samples were lost due to hemolysis. In the ICAD patients that were medically treated, the attrition in sample number may impact the significance of our observation that medical treatment gradually elevates the VEGF-A_{165a/b} ratio. However, the ICAD patients with missing samples showed no difference on demographic and clinical characteristics compared to those with all scheduled sample measuring, suggesting missing at random and consequently limited influence on VEGF-A₁₆₅ isoform levels (Supplemental Table 2). Finally, the plasma levels of VEGF-A₁₆₅ could be influenced by various factors such as diseases, medication, and individual variance. Several efforts have been made to address this limitation, including

a comprehensive inclusion and exclusion criteria, application of a homogeneous protocol of medical and surgical treatment for each disease, duplicate evaluations of VEGF-A₁₆₅ isoforms at sequential time points examined simultaneously, and strict intra-assay coefficient of variation for the measurements of VEGF-A₁₆₅ isoforms.

SUMMARY

Our results show that VEGF-A₁₆₅ isoforms are distinct between MMD and ICAD. This study indicates that an increased VEGF-A_{165a/b} ratio is associated with MMD. It also indicates that both intensive medical management and surgical revascularization elevate the VEGF-A_{165a/b} ratio in ICAD patients. These findings justify future additional evaluations to better understand the mechanisms involved in the alternative splicing of VEGF-A in ICAD and MMD, and the potential roles of VEGF-A_{165a} and VEGF-A_{165b} in the outcomes after treatment of these patients.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We are grateful to the Cedars-Sinai Medical Center and UCLA Stroke Center members for their support and continuous collaboration. Also, we warmly thank the research coordination team led by Antoinette Anderson.

SOURCES OF FUNDING

This work was supported by grants from the American Heart Association (14ISA20870000), NIH (K23 NS079477-01A1), and the Science and Technology Department of Zhejiang Province (2015C34007) and by the philanthropic support of the Margo and Irwin Winkler Family.

REFERENCES

- [1]. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. *Annual review of pathology* 2007;2:251–75.
- [2]. Dai J, Rabie AB. VEGF: an essential mediator of both angiogenesis and endochondral ossification. *Journal of dental research* 2007;86:937–50. [PubMed: 17890669]
- [3]. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? *Nature reviews Cancer* 2008;8:880–7. [PubMed: 18923433]
- [4]. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. *Cancer research* 2002;62:4123–31. [PubMed: 12124351]
- [5]. De Silva DA, Woon FP, Lee MP, Chen CP, Chang HM, Wong MC. South Asian patients with ischemic stroke: intracranial large arteries are the predominant site of disease. *Stroke* 2007;38:2592–4. [PubMed: 17656660]
- [6]. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. *Stroke* 2008;39:2396–9. [PubMed: 18535283]
- [7]. Maas MB, Lev MH, Ay H, Singhal AB, Greer DM, Smith WS, et al. Collateral vessels on CT angiography predict outcome in acute ischemic stroke. *Stroke* 2009;40:3001–5. [PubMed: 19590055]
- [8]. Lima FO, Furie KL, Silva GS, Lev MH, Camargo EC, Singhal AB, et al. The pattern of leptomeningeal collaterals on CT angiography is a strong predictor of long-term functional

outcome in stroke patients with large vessel intracranial occlusion. *Stroke* 2010;41:2316–22. [PubMed: 20829514]

- [9]. Liebeskind DS, Cotsonis GA, Saver JL, Lynn MJ, Turan TN, Cloft HJ, et al. Collaterals dramatically alter stroke risk in intracranial atherosclerosis. *Annals of neurology* 2011;69:963–74. [PubMed: 21437932]
- [10]. Liebeskind DS, Cotsonis GA, Saver JL, Lynn MJ, Cloft HJ, Chimowitz MI. Collateral circulation in symptomatic intracranial atherosclerosis. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 2011;31:1293–301.
- [11]. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. *The New England journal of medicine* 2005;352:1305–16. [PubMed: 15800226]
- [12]. Wityk RJ, Lehman D, Klag M, Coresh J, Ahn H, Litt B. Race and sex differences in the distribution of cerebral atherosclerosis. *Stroke* 1996;27:1974–80. [PubMed: 8898801]
- [13]. Williams JE, Chimowitz MI, Cotsonis GA, Lynn MJ, Waddy SP. Gender differences in outcomes among patients with symptomatic intracranial arterial stenosis. *Stroke* 2007;38:2055–62. [PubMed: 17540969]
- [14]. Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. *Lancet Neurol* 2008;7:1056–66. [PubMed: 18940695]
- [15]. Matsunaga T, Warltier DC, Weihrauch DW, Moniz M, Tessmer J, Chilian WM. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. *Circulation* 2000;102:3098–103. [PubMed: 11120701]
- [16]. Toyota E, Warltier DC, Brock T, Ritman E, Kolz C, O'Malley P, et al. Vascular endothelial growth factor is required for coronary collateral growth in the rat. *Circulation* 2005;112:2108–13. [PubMed: 16203926]
- [17]. Clayton JA, Chalothorn D, Faber JE. Vascular endothelial growth factor-A specifies formation of native collaterals and regulates collateral growth in ischemia. *Circulation research* 2008;103:1027–36. [PubMed: 18802023]
- [18]. Rafat N, Beck G, Pena-Tapia PG, Schmiedek P, Vajkoczy P. Increased levels of circulating endothelial progenitor cells in patients with Moyamoya disease. *Stroke* 2009;40:432–8. [PubMed: 19095988]
- [19]. Bang OY, Chung JW, Kim SJ, Oh MJ, Kim SY, Cho YH, et al. Caveolin-1, Ring finger protein 213, and endothelial function in Moyamoya disease. *International journal of stroke : official journal of the International Stroke Society* 2016;11:999–1008. [PubMed: 27462098]
- [20]. Laiwalla AN, Ooi YC, Van De Wiele B, Ziv K, Brown A, Liou R, et al. Rigorous anaesthesia management protocol for patients with intracranial arterial stenosis: a prospective controlled-cohort study. *BMJ open* 2016;6:e009727.
- [21]. Gonzalez NR, Dusick JR, Connolly M, Bounni F, Martin NA, Van de Wiele B, et al. Encephaloduroarteriosynangiosis for adult intracranial arterial steno-occlusive disease: long-term single-center experience with 107 operations. *J Neurosurg* 2015;123:654–61. [PubMed: 26067617]
- [22]. Taimeh Z, Loughran J, Birks EJ, Bolli R. Vascular endothelial growth factor in heart failure. *Nature reviews Cardiology* 2013;10:519–30. [PubMed: 23856679]
- [23]. Greenberg DA, Jin KL. Vascular endothelial growth factors (VEGFs) and stroke. *Cell Mol Life Sci* 2013;70:1753–61. [PubMed: 23475070]
- [24]. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. *Circulation* 2003;108:1933–8. [PubMed: 14504183]
- [25]. Kikuchi R, Nakamura K, MacLauchlan S, Ngo DT, Shimizu I, Fuster JJ, et al. An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease. *Nature medicine* 2014;20:1464–71.

- [26]. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nature medicine* 1999;5:434–8.
- [27]. Iwaguro H, Yamaguchi J, Kalka C, Murasawa S, Masuda H, Hayashi S, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. *Circulation* 2002;105:732–8. [PubMed: 11839630]
- [28]. Tongers J, Roncalli JG, Losordo DW. Role of endothelial progenitor cells during ischemia-induced vasculogenesis and collateral formation. *Microvascular research* 2010;79:200–6. [PubMed: 20144623]
- [29]. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. *Journal of cell science* 2008;121:3487–95. [PubMed: 18843117]
- [30]. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. *Lancet (London, England)* 2002;359:1740–5.
- [31]. Colao A, Di Somma C, Cascella T, Pivonello R, Vitale G, Grasso LF, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. *European journal of endocrinology* 2008;159:389–97. [PubMed: 18603571]
- [32]. Berryman DE, Glad CA, List EO, Johannsson G. The GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations. *Nature reviews Endocrinology* 2013;9:346–56.
- [33]. Saber H, Himali JJ, Beiser AS, Shoamanesh A, Pikula A, Roubenoff R, et al. Serum Insulin-Like Growth Factor 1 and the Risk of Ischemic Stroke: The Framingham Study. *Stroke* 2017;48:1760–5. [PubMed: 28596451]
- [34]. Malik J, Stulc T, Wichterle D, Melenovsky V, Chytilova E, Lacinova Z, et al. Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. *Physiological research* 2008;57:919–25. [PubMed: 18052685]
- [35]. Gonzalez NR, Liou R, Kurth F, Jiang H, Saver J. Antiangiogenesis and medical therapy failure in intracranial atherosclerosis. *Angiogenesis* 2017.
- [36]. van der Bilt JD, Borel Rinkes IH. Surgery and angiogenesis. *Biochimica et biophysica acta* 2004;1654:95–104. [PubMed: 14984770]

Figure 1.

Flow diagram demonstrating the numbers of patients (N) and samples (n) in each group and time point, as well as the attrition quantities with their reasons at each step. In the surgical patients, only 2 samples were lost due to sample hemolysis at 6-month follow up. An inter-duplicate variance of ELISA measurements 20% was defined as invalid measurement and the data was excluded.

Figure 2.

Comparison of baseline VEGF-A₁₆₅ (A), VEGF-A_{165a} (B), and VEGF-A_{165b} (C) levels in ICAD, MMD, and controls. The box plots graph shows that MMD patients have a significantly higher level of VEGF-A_{165a} compared to controls ($p=0.026$) and a significantly lower level of VEGF-A_{165b} compared to ICAD ($p=0.0006$) and controls ($p=0.0070$). The total levels of VEGF-A₁₆₅ were not different between the three groups ($p=0.31$). The highest levels of VEGF-A_{165a} were observed in MMD, while the highest levels of VEGF-A_{165b} were seen in ICAD.

VEGF, vascular endothelial growth factor; ICAD, intracranial atherosclerotic disease; MMD, moyamoya disease; *, $p<0.05$; **, $p<0.01$; ***, $p<0.001$.

Figure 3.

Elevation of VEGF-A_{165a/b} ratio within one week after surgery according to etiology. The bar graph shows that the VEGF-A_{165a/b} ratio elevated in all the groups, but only in ICAD was the increase significant (p=0.026).

VEGF, vascular endothelial growth factor; ICAD, intracranial atherosclerotic disease; MMD, moyamoya disease; *, p<0.05.

Figure 4.

Box plots of VEGF-A₁₆₅a (A), VEGF-A₁₆₅b (B), and VEGF-A₁₆₅a/b ratio (C) at different time points after surgical revascularization (in red) and medical treatment (in blue) in ICAD patients. The upper halves of panel A, B, and C show the surgical effects on the variations of VEGF-A₁₆₅a, VEGF-A₁₆₅b, and the VEGF-A₁₆₅a/b ratio, respectively. Surgery significantly increased the VEGF-A₁₆₅a/b ratio within one week after surgery ($p=0.026$), with the ratio gradually declining to the lowest value at six months. Additionally, the VEGF-A₁₆₅b level within one week was significantly lower than at baseline ($p=0.047$). The lower halves of panel A, B, and C illustrate the medical effect on the VEGF-A₁₆₅a level, the VEGF-A₁₆₅b level, and the VEGF-A₁₆₅a/b ratio, respectively. The VEGF-A₁₆₅a/b ratio progressively increased and reached its peak after three months during intensive medical management ($p=0.028$). A significant difference between baseline and three months was also found in the VEGF-A₁₆₅a level ($p=0.015$). VEGF-A₁₆₅b levels did not change during follow-up ($p=0.38$).

VEGF, vascular endothelial growth factor; ICAD, intracranial atherosclerotic disease; *, $p<0.05$; **, $p<0.01$.

Table 1.**Inclusion and Exclusion Criteria**

Inclusion criteria	
1.	70% stenosis of intracranial large artery diagnosed by catheter, MR, or CT angiography.
2.	Patient is willing and able to return for all follow-up visits.
3.	Patient understands the purpose and requirements of the study, can make him- or herself understood, and has provided consent.
Exclusion criteria	
1.	Patients with any known vasculitic disease, viral vasculopathy, neurosyphilis, any other intracranial infection, any intracranial stenosis associated with cerebrospinal fluid pleocytosis, radiation-induced vasculopathy, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, benign angiopathy of the central nervous system, postpartum angiopathy, suspected vasospastic process, or suspected recanalized embolus.
2.	Patients with presence of any of the following unequivocal cardiac sources of embolism: chronic or paroxysmal atrial fibrillation, mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within three months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction <30%.
3.	Intracranial tumor or vascular malformation.
4.	Any hemorrhagic infarct within 14 days before enrollment or any other intracranial hemorrhage (subarachnoid, subdural, or epidural) within 30 days.
5.	Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 180 days after enrollment.
6.	Severe neurologic deficit that renders the patient not independent.

Table 2.**Diagnostic Criteria for ICAD and MMD**

Diagnostic Criteria for ICAD	
1. Imaging features of atherosclerosis such as calcification of the intracranial vessels, and	
2. at least one of the following:	
a. insulin dependent diabetes for at least 15 years	
b. at least two of the following atherosclerotic risk factors:	
• hypertension (BP ≥ 140/90 mmHg or on antihypertensive therapy);	
• dyslipidemia (LDL > 130 mg/dl or HDL < 40 mg/dl or fasting triglycerides > 150 mg/dl or on lipid lowering therapy);	
• smoking history;	
• non-insulin-dependent diabetes or insulin dependent diabetes of less than 15 years duration;	
• family history of any of the following: myocardial infarction, coronary artery bypass, coronary artery angioplasty or stenting, stroke, carotid endarterectomy or stenting, peripheral vascular surgery in parent or sibling who was < 55 years of age for men or < 65 years of age for women at the time of the event;	
• history of any of the following: myocardial infarction, coronary artery bypass, coronary angioplasty or stenting, carotid endarterectomy or stenting, or peripheral vascular surgery for atherosclerotic disease;	
c. any stenosis of an extracranial carotid or vertebral artery, subclavian artery, coronary artery, iliac or femoral artery, other lower or upper extremity artery, mesenteric artery, or renal artery that was documented by noninvasive vascular imaging or catheter angiography and is considered atherosclerotic;	
d. aortic arch atheroma documented by noninvasive vascular imaging or catheter angiography;	
e. any aortic aneurysm documented by noninvasive vascular imaging or catheter angiography that is considered atherosclerotic.	
Diagnostic Criteria for MMD	
1. Bilateral intracranial arterial stenosis of the distal internal carotid arteries and the origin of the anterior cerebral and middle cerebral arteries, and	
2. evidence of moyamoya collaterals in angiography, and	
3. absence of any risk factors for atherosclerosis.	

Table 3.Univariate Analyses of the Factors Potentially Related with VEGFA_{165a/b} Ratio

Variable	P
Demographic factors	
Age	0.044 *
Gender	0.98
Race	0.14
Medical history	
Coronary artery disease	0.84
Vascular risk factors	
Smoking history	0.89
Drinking history	0.80
Hypertension	0.078
Hyperlipidemia	0.10
Type 2 diabetes mellitus	0.78
Other factors	
Etiology	0.015 *
Treatment	0.13
Time after treatment	0.15

* Statistically significant